WallStreetZenWallStreetZen

NASDAQ: ITRM
Iterum Therapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ITRM

Based on 1 analyst offering 12 month price targets for Iterum Therapeutics PLC

Min Forecast
$9.00+1,225.48%
Avg Forecast
$9.00+1,225.48%
Max Forecast
$9.00+1,225.48%

Should I buy or sell ITRM stock?

Based on 1 analyst offering ratings for Iterum Therapeutics PLC.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ITRM's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ITRM as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ITRM stock forecasts and price targets.

ITRM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-08

1 of 1

Forecast return on equity

Is ITRM forecast to generate an efficient return?

Company
-229.78%
Industry
130.77%
Market
-49.74%
ITRM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ITRM forecast to generate an efficient return on assets?

Company
26.26%
Industry
47.39%
ITRM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ITRM earnings per share forecast

What is ITRM's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.54
Avg 2 year Forecast
$0.10
Avg 3 year Forecast
$0.75

ITRM revenue forecast

What is ITRM's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$15.1M
Avg 2 year Forecast
$59.6M

ITRM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ITRM$0.68$9.00+1,225.48%Buy
CLGN$2.58$11.50+345.56%Strong Buy
CASI$2.01$4.00+99.00%Buy
PPBT$0.60N/AN/A
RENB$0.18N/AN/A
View Top Biotech Stocks

Iterum Therapeutics Stock Forecast FAQ

Is Iterum Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ITRM) stock is to Buy ITRM stock.

Out of 1 analyst, 0 (0%) are recommending ITRM as a Strong Buy, 1 (100%) are recommending ITRM as a Buy, 0 (0%) are recommending ITRM as a Hold, 0 (0%) are recommending ITRM as a Sell, and 0 (0%) are recommending ITRM as a Strong Sell.

If you're new to stock investing, here's how to buy Iterum Therapeutics stock.

What is ITRM's earnings growth forecast for 2025-2027?

(NASDAQ: ITRM) Iterum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Iterum Therapeutics's earnings in 2025 is -$24,076,000.On average, 1 Wall Street analyst forecast ITRM's earnings for 2025 to be -$24,114,729, with the lowest ITRM earnings forecast at -$24,114,729, and the highest ITRM earnings forecast at -$24,114,729. On average, 1 Wall Street analyst forecast ITRM's earnings for 2026 to be $4,465,691, with the lowest ITRM earnings forecast at $4,465,691, and the highest ITRM earnings forecast at $4,465,691.

In 2027, ITRM is forecast to generate $33,492,680 in earnings, with the lowest earnings forecast at $33,492,680 and the highest earnings forecast at $33,492,680.

What is ITRM's revenue growth forecast for 2026-2027?

(NASDAQ: ITRM) Iterum Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.

Iterum Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ITRM's revenue for 2026 to be $674,319,281, with the lowest ITRM revenue forecast at $674,319,281, and the highest ITRM revenue forecast at $674,319,281.

In 2027, ITRM is forecast to generate $2,661,551,598 in revenue, with the lowest revenue forecast at $2,661,551,598 and the highest revenue forecast at $2,661,551,598.

What is ITRM's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ITRM) forecast ROA is 26.26%, which is lower than the forecast US Biotechnology industry average of 47.39%.

What is ITRM's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ITRM price target, the average ITRM price target is $9.00, with the highest ITRM stock price forecast at $9.00 and the lowest ITRM stock price forecast at $9.00.

The Wall Street analyst predicted that Iterum Therapeutics's share price could reach $9.00 by May 8, 2026. The average Iterum Therapeutics stock price prediction forecasts a potential upside of 1,225.48% from the current ITRM share price of $0.68.

What is ITRM's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ITRM) Iterum Therapeutics's current Earnings Per Share (EPS) is -$0.81. On average, analysts forecast that ITRM's EPS will be -$0.54 for 2025, with the lowest EPS forecast at -$0.54, and the highest EPS forecast at -$0.54. On average, analysts forecast that ITRM's EPS will be $0.10 for 2026, with the lowest EPS forecast at $0.10, and the highest EPS forecast at $0.10. In 2027, ITRM's EPS is forecast to hit $0.75 (min: $0.75, max: $0.75).

What is ITRM's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ITRM) forecast ROE is -229.78%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.